Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including...
angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(9)
•••
JocetooBad
X
View Profile
View Bullboard History
Comment by
JocetooBad
on Feb 16, 2024 11:54am
RE:Ah, what will the New Year bring?
Dude, I'm in the same boat. Will a government grant save the day on the very last minute? Indeed 2024 will tell.
(35)
•••
Dudeforever
X
View Profile
View Bullboard History
Post by
Dudeforever
on Dec 07, 2023 4:52pm
Ah, what will the New Year bring?
2024 will either be HEM's last year, or else one of their many claims actually proves to have substance. Thomas has drained his cup of credibility. Raising money is going to be almost
...more
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 23, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(1)
•••
Budaman
X
View Profile
View Bullboard History
Comment by
Budaman
on Oct 31, 2023 7:41pm
RE:$HEM experience is very bad
Same person, multiple new accounts, and all of them full of negativity, designed to try and get people to sell. I was waiting for the wanna be trolls to reappear with this stock, and now here
...more
(0)
•••
Gefele1424
X
View Profile
View Bullboard History
Post by
Gefele1424
on Oct 31, 2023 11:35am
$HEM experience is very bad
The company's financial statements show declining revenue; the company is not keeping up with industry trends. In my experience, this company is totally scammy.
(0)
•••
hexekay
X
View Profile
View Bullboard History
Post by
hexekay
on Oct 31, 2023 9:59am
Dark Days for $HEM: Shareholders Left Empty-Handed as Stock
$HEM's stock as a beacon of hope now themselves in the dark as the company's fortunes crumble. The market value of $HEM's stock has withered, leaving shareholders with little to show for
...more
(0)
•••
Williammax
X
View Profile
View Bullboard History
Post by
Williammax
on Oct 31, 2023 8:44am
$HEM's Stock Fails to Deliver as Services Struggle.
$HEM's stock, which was once a beacon of hope among penny stocks, has lost its shine as the company's services falter, causing a drop in its market value. $HEM's stock has been a
...more
(0)
•••
Marcos7
X
View Profile
View Bullboard History
Post by
Marcos7
on Oct 30, 2023 11:59am
Bad experience with $HEM .
I came to notice that the stock is performing very bad and the financial condition shows how the investors are going to suffer . I lost my money by trusting this kind of stock . Never suggest this to
...more
(0)
•••
Carlos777
X
View Profile
View Bullboard History
Post by
Carlos777
on Oct 30, 2023 11:58am
HEM stock disappointment, outdated financial data
HEM'S lack of profitability and outdated financial data, investing in $HEM has been a frustrating experience.the company has consistently failed to turn a profit, leaving shareholders like me in a
...more
(0)
•••
Jamesmacho
X
View Profile
View Bullboard History
Post by
Jamesmacho
on Oct 30, 2023 9:06am
The Ongoing Struggles of $HEM Stockholders
Investors in $HEM have faced a turbulent year, marked by a persistent downward trajectory in the stock price. This disappointing trend has left many questioning their investment decisions. The company
...more
(33)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on May 02, 2023 7:49pm
NCP
Great news for NCP...not so good for the sp...not even a blip!!!! What ever happened to the Canadian researcher that they collaborated with on this 2 years ago ?????? Why no word on that aspect
...more
(3)
•••
PowerOfTheSun
X
View Profile
View Bullboard History
Post by
PowerOfTheSun
on Apr 06, 2023 1:12pm
Force Family Office webinar
(33)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Apr 03, 2023 8:29pm
Hmmm
That's an interesting PR. Gotta give it to Smeenk, he certainly works for his money...in weird ways! Podiatry is actually a genius idea, they see all these CLI pts well before they
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 03, 2023 9:22am
New Press Release - Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
Calgary, Alberta--(Newsfile Corp. - April 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 29, 2023 12:46pm
New Press Release - Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia "CLI...
read article.
(9)
•••
JocetooBad
X
View Profile
View Bullboard History
Comment by
JocetooBad
on Mar 22, 2023 4:31pm
RE:HEM has piqued the interest of industry participants.
Nice to meet you, bot #4444!
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study